H. Checkoway and L. Nelson, Epidemiologic Approaches to the Study of Parkinson??s Disease Etiology, Epidemiology, vol.10, issue.3, pp.327-336, 1999.
DOI : 10.1097/00001648-199905000-00023

S. Fahn and G. Cohen, The oxidant stress hypothesis in Parkinson's disease: Evidence supporting it, Annals of Neurology, vol.43, issue.6, pp.804-812, 1992.
DOI : 10.1002/ana.410320616

C. Olanow, Oxidation reactions in Parkinson's disease, Neurology, vol.40, pp.32-37, 1990.
DOI : 10.1002/ana.24011

L. Migliore, L. Petrozzi, and C. Lucetti, Oxidative damage and cytogenetic analysis in leukocytes of Parkinson's disease patients, Neurology, vol.58, issue.12, pp.1809-1815, 2002.
DOI : 10.1212/WNL.58.12.1809

P. Cerutti, Oxy-radicals and cancer, The Lancet, vol.344, issue.8926, pp.862-863, 1994.
DOI : 10.1016/S0140-6736(94)92832-0

C. Lücking, A. Dürr, and V. Bonifati, Gene, New England Journal of Medicine, vol.342, issue.21, pp.1560-1567, 2000.
DOI : 10.1056/NEJM200005253422103

A. West, D. Maraganore, and J. Crook, Functional association of the parkin gene promoter with idiopathic Parkinson's disease, Human Molecular Genetics, vol.11, issue.22, pp.2787-2792, 2002.
DOI : 10.1093/hmg/11.22.2787

R. Cesari, E. Martin, and G. Calin, Parkin, a gene implicated in autosomal recessive juvenile parkinsonism, is a candidate tumor suppressor gene on chromosome 6q25-q27, Proceedings of the National Academy of Sciences, vol.100, issue.10, pp.5956-5961, 2003.
DOI : 10.1073/pnas.0931262100

S. Denison, G. Callahan, N. Becker, L. Phillips, and D. Smith, Characterization of FRA6E and its potential role in autosomal recessive juvenile parkinsonism and ovarian cancer, Genes, Chromosomes and Cancer, vol.97, issue.1, pp.40-52, 2003.
DOI : 10.1002/gcc.10236

S. Basu, J. Nagy, and S. Pal, The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor/vascular endothelial growth factor, Nature Medicine, vol.7, issue.5, pp.569-574, 2001.
DOI : 10.1038/87895

J. Siple, D. Schneider, W. Wanlass, and B. Rosenblatt, Levodopa Therapy and the Risk of Malignant Melanoma, Annals of Pharmacotherapy, vol.15, issue.3, pp.382-385, 2000.
DOI : 10.1345/aph.19150

H. Checkoway, F. Farin, P. Costa-mallen, S. Kirchner, and L. Costa, Genetic polymorphisms in Parkinson's disease, Neurotoxicology, vol.19, pp.635-644, 1998.

R. Wolf, G. Smith, and P. Cytochrome, Metabolic Polymorphisms and Cancer Susceptibility, IARC Scientific Publications Lyon: International Agency for Research on Cancer, issue.148, pp.209-229, 1999.
DOI : 10.1007/3-540-30683-8_1053

M. Benedetti, D. Maraganore, and J. Bower, Hysterectomy, menopause, and estrogen use preceding Parkinson's disease: An exploratory case-control study, Movement Disorders, vol.64, issue.5, pp.830-837, 2001.
DOI : 10.1002/mds.1170

K. Mcnaught, C. Olanow, B. Halliwell, O. Isacson, and P. Jenner, Failure of the ubiquitin???proteasome system in Parkinson's disease, Nature Reviews Neuroscience, vol.275, issue.8, pp.589-594, 2001.
DOI : 10.1038/35086067

B. Mitchell, The Proteasome ??? An Emerging Therapeutic Target in Cancer, New England Journal of Medicine, vol.348, issue.26, pp.2597-2598, 2003.
DOI : 10.1056/NEJMp030092

K. Westlund and A. Hougen, CANCER AS A CAUSE OF DEATH AMONG PATIENTS WITH OTHER CHRONIC DISEASES, Journal of the American Medical Association, vol.162, issue.10, p.1003, 1956.
DOI : 10.1001/jama.1956.02970270063024

A. Barbeau and J. Joly, Parkinsonism and cancer, Union Med Can, vol.92, pp.169-174, 1963.

M. Hoehn and M. Yahr, Parkinsonism: onset, progression, and mortality, Neurology, vol.17, issue.5, pp.427-442, 1967.
DOI : 10.1212/WNL.17.5.427

P. Pritchard, . Iii, and M. Netsky, Prevalence of neoplasms and causes of death in paralysis agitans A necropsy study, Neurology, vol.23, issue.3, pp.215-222, 1973.
DOI : 10.1212/WNL.23.3.215

H. Harada, S. Nishikawa, and K. Takahashi, Epidemiology of Parkinson's Disease in a Japanese City, Archives of Neurology, vol.40, issue.3, pp.151-154, 1983.
DOI : 10.1001/archneur.1983.04050030045008

B. Jansson and J. Jankovic, Low cancer rates among patients with Parkinson's disease, Annals of Neurology, vol.162, issue.5, pp.505-509, 1985.
DOI : 10.1002/ana.410170514

A. Rajput, K. Offord, C. Beard, and L. Kurland, A case-control study of smoking habits, dementia, and other illnesses in idiopathic Parkinson's disease, Neurology, vol.37, issue.2, pp.226-232, 1987.
DOI : 10.1212/WNL.37.2.226

J. Gorell, C. Johnson, and B. Rybicki, Parkinson's disease and its comorbid disorders: An analysis of Michigan mortality data, 1970 to 1990, Neurology, vol.44, issue.10, pp.1865-1868, 1970.
DOI : 10.1212/WNL.44.10.1865

H. Møller, L. Mellemkjaer, J. Mclaughlin, and J. Olsen, Occurrence of different cancers in patients with Parkinson's disease, BMJ, vol.310, issue.6993, pp.1500-1501, 1995.
DOI : 10.1136/bmj.310.6993.1500

Y. Ben-shlomo and M. Marmot, Survival and cause of death in a cohort of patients with parkinsonism: possible clues to aetiology?, Journal of Neurology, Neurosurgery & Psychiatry, vol.58, issue.3, pp.293-299, 1995.
DOI : 10.1136/jnnp.58.3.293

R. Raschetti, S. Spila-alegiani, N. Vanacore, C. Ancona, and G. Meco, Mortality in a population-based cohort of patients treated with antiparkinsonian drugs, Acta Neurologica Scandinavica, vol.79, issue.1, pp.20-26, 1998.
DOI : 10.1111/j.1600-0404.1998.tb00604.x

N. Vanacore, S. Spila-alegiani, R. Raschetti, and G. Meco, Mortality cancer risk in parkinsonian patients: A population-based study, Neurology, vol.52, issue.2, pp.395-398, 1999.
DOI : 10.1212/WNL.52.2.395

Y. Minami, R. Yamamoto, M. Nishikouri, A. Fukao, and S. Hisamichi, Mortality and cancer incidence in patients with Parkinson's disease, Journal of Neurology, vol.247, issue.6, pp.429-434, 2000.
DOI : 10.1007/s004150070171

A. Elbaz, B. Peterson, and P. Yang, Nonfatal Cancer Preceding Parkinson???s Disease: A Case-Control Study, Epidemiology, vol.13, issue.2, pp.157-164, 2002.
DOI : 10.1097/00001648-200203000-00010

N. Breslow and N. Day, Statistical methods in cancer research The design and analysis of cohort studies, IARC Scientific Publications No. Lyon: International Agency for Research on Cancer, vol.2, issue.82, 1987.

L. Melton, History of the Rochester Epidemiology Project, Mayo Clinic Proceedings, vol.71, issue.3, pp.266-274, 1996.
DOI : 10.4065/71.3.266

J. Bower, D. Maraganore, S. Mcdonnell, and W. Rocca, Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976-1990, Neurology, vol.52, issue.6, pp.1214-1220, 1976.
DOI : 10.1212/WNL.52.6.1214

A. Elbaz, J. Bower, and B. Peterson, Survival Study of Parkinson Disease in Olmsted County, Minnesota, Archives of Neurology, vol.60, issue.1, pp.91-96, 2003.
DOI : 10.1001/archneur.60.1.91

R. Uitti, J. Ahlskog, and D. Maraganore, Levodopa therapy and survival in idiopathic Parkinson's disease: Olmsted County project, Neurology, vol.43, issue.10, pp.1918-1926, 1993.
DOI : 10.1212/WNL.43.10.1918

E. Korn, B. Graubard, and D. Midthune, Time-to-event analysis of longitudinal follow-up of a survey: choice of the time-scale, Am J Epidemiol, vol.145, pp.72-80, 1997.

T. Therneau and P. Gambsch, Modeling survival data: extending the Cox model, 2000.
DOI : 10.1007/978-1-4757-3294-8

D. Shopland, A. Harras, B. Edwards, W. Blot, and L. Ries, Cigarette smoking as a cause of cancer, Cancer rates and risks. NIH Publication No. 96-691. Bethesda, Maryland: National Cancer Institute, pp.67-72, 1996.

H. Checkoway, N. Pearce, J. Hickey, and J. Dement, Latency Analysis in Occupational Epidemiology, Archives of Environmental Health: An International Journal, vol.106, issue.2, pp.95-100, 1990.
DOI : 10.1002/1097-0142(19801215)46:12<2736::AID-CNCR2820461233>3.0.CO;2-L

P. Morrish, J. Rakshi, D. Bailey, G. Sawle, and D. Brooks, Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET, Journal of Neurology, Neurosurgery & Psychiatry, vol.64, issue.3, pp.314-319, 1998.
DOI : 10.1136/jnnp.64.3.314

A. Feinstein, Clinical epidemiology: The architecture of clinical research, Statistics in Medicine, vol.117, issue.11, 1985.
DOI : 10.1002/sim.4780141110

S. Parashos, D. Maraganore, O. Brien, P. Rocca, and W. , Medical Services Utilization and Prognosis in Parkinson Disease: A Population-Based Study, Mayo Clinic Proceedings, vol.77, issue.9, pp.918-925, 2002.
DOI : 10.1016/S0025-6196(11)62259-3

C. Tanner, L. Nelson, S. Van-den-eeden, D. Harrington, and A. Bernstein, Skin pigmentation and risk of Parkinson's disease (PD), Neurology, vol.52, p.540, 1999.

M. Lerner and R. Goldman, SKIN COLOUR, MPTP, AND PARKINSON'S DISEASE, The Lancet, vol.330, issue.8552, p.212, 1987.
DOI : 10.1016/S0140-6736(87)90786-0

T. Diepgen and V. Mahler, The epidemiology of skin cancer, British Journal of Dermatology, vol.50, issue.s61, pp.1-6, 2002.
DOI : 10.1023/A:1008980919928